A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation

Daclizumab and basiliximab, engineered human IgG monoclonal antibodies to the interleukin‐2 (IL‐2) receptor α‐subunit, were approved to prevent acute rejection after rnal transplantation. Daclizumab was studied in adult and pediatric renal allograft recipients, liver allograft recipients, and calcineurin‐sparing protocols in renal transplant recipients. Basiliximab was studied in renal allograft recipients and subgroups of recipients of living‐related and cadaveric transplants, and in patients with diabetes mellitus. Both agents reduced acute rejection and were associated with few adverse effects. However, information regarding their long‐term effects on infection, malignancy, chronic rejection, and patient survival must be available before a final decision is made regarding their proper administration. We propose that a likely role the drugs will play in the field of solid organ transplantation is in new protocols that allow sparing of other more toxic immunosuppressive agents.

[1]  A. Novick,et al.  Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. , 1996, Transplantation.

[2]  D. Hernández-Gallardo,et al.  Successful transplantation of a liver graft with a calcified hydatid cyst after back-table resection. , 1995, Transplantation.

[3]  J. Kovarik,et al.  Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. , 1997, Transplantation.

[4]  S. Light,et al.  Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. , 1998, Transplantation proceedings.

[5]  R. Zietse,et al.  A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF MONOCLONAL ANTI‐INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION , 1995, Transplantation.

[6]  M. Schreier,et al.  Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. , 1995, Transplantation.

[7]  D. Mould,et al.  A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. , 1997, Transplantation.

[8]  M. Pescovitz,et al.  HUMANIZED MONOCLONAL ANTI INTERLEUKIN-2 RECEPTOR (IL-2R) ANTIBODY DACLIZUMAB (ZENAPAX®) IN PEDIATRIC (Ped) RENAL TRANSPLANTATION (Tx) , 1998 .

[9]  B. Nashan,et al.  Reduction of acute allograft rejection by daclizumab , 1999 .

[10]  T. Breidenbach,et al.  BASILIXIMAB (SIMULECT™) REDUCES ACUTE REJECTIONS, CMV-INFECTIONS AND DURATION OF HOSPITAL STAY IN RENAL ALLOGRAFT PATIENTS , 1998 .

[11]  B. Nashan,et al.  Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. , 1999, Transplantation.

[12]  J. Kovarik,et al.  Influence Of The Duration Of Il-2 Receptor (il-2r) Blockade On The Incidence Of Acute Rejection Episodes In Renal Transplantation , 1998 .

[13]  J. Kovarik,et al.  Disposition and immunodynamics of basiliximab in liver allograft recipients , 1998, Clinical pharmacology and therapeutics.

[14]  J. Soulillou,et al.  Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.

[15]  M. Hall,et al.  Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. , 1999, Transplantation.

[16]  T. Waldmann,et al.  A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. , 1991, Transplantation.